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Coronary artery bypass (CAB) without the use of car-
diopulmonary bypass (CPB) has been performed since the
earliest days of coronary surgery. Recently, interest in off-
pump bypass has increased rapidly as a way to perform CAB
at less cost and morbidity. Most current publications on min-
imally invasive direct coronary artery bypass (MIDCAB) deal
with surgical technique, feasibility, and early results. The
recent review of MIDCAB grafting by Calafiore and associ-
ates1 provides an excellent summary of this subject, as well as
addressing concerns with the procedure. The evolution of this
procedure has also seen the emergence of complications asso-
ciated with MIDCAB that may represent an under-reporting
of problems.2,3 We report the case of a patient requiring ortho-
topic cardiac transplantation after MIDCAB.
Clinical summary. A 68-year-old man was admitted on
March 4, 1997, with shortness of breath and extreme fatigue
with minimal exertion consistent with severe congestive heart
failure. Five years before this admission he was evaluated for
angina and found to have an isolated 90% stenosis of the left
anterior descending (LAD) coronary artery and an ejection
fraction of 45%. Successful percutaneous transluminal coro-
nary angioplasty (PTCA) was accomplished with relief of
angina. Two years later recurrent angina and LAD stenosis
developed and he again responded to successful PTCA. Six
months before admission, angina again developed. The
patient was found to have a long stenosis of the LAD as an
isolated lesion and an ejection fraction of 35%. MIDCAB
with a left internal thoracic artery graft to the LAD was per-
formed at another institution and he was discharged without
angina. Three weeks after discharge, angina developed yet
again, with the additional symptoms of shortness of breath
with moderate exertion. Cardiac catheterization revealed a
severe stenosis of the left internal thoracic artery graft at its
anastomosis to the LAD, as well as an ejection fraction of
20%. Attempted PTCA of the anastomosis was unsuccessful.
Further clinical deterioration prompted transfer to our facility
with admission for intravenous inotropic support. Cardiac
catheterization at that admission showed a cardiac index of
1.29 L/min per square meter, a pulmonary artery pressure of
65/37 mm Hg, a pulmonary capillary wedge pressure of 32
mm Hg, and a central venous pressure of 19 mm Hg.
Deteriorating clinical status, as well as rising hepatic enzyme
levels and decreasing renal function, prompted consideration
for cardiac transplantation. On March 1, 1997, orthotopic car-
diac transplantation from a 35-year-old male donor was suc-
cessfully accomplished. The postoperative course was
uneventful, and the patient is doing well at home without
symptoms at this time.
Discussion. The surgical treatment of ischemic heart dis-
ease has a long and interesting history. The initial direct
approaches to coronary artery obstruction were done without
the use of CPB.1,2 However, without CPB for hemodynamic
support, the extent and accuracy of the coronary surgery often
suffered. Subsequently, median sternotomy, CPB, and
myocardial protection became the cornerstones of modern
coronary artery surgery, allowing an excellent operating envi-
ronment and access to all coronary arteries. Recently a rapid
recurrence of interest in off-pump CAB as a form of mini-
mally invasive CAB has arisen.1 This world-wide phenome-
non follows the explosion of laparoscopic techniques in gen-
eral surgery in an attempt to extend minimally invasive
technique into thoracic surgery. The majority of the recent lit-
erature on beating-heart CAB has been focused on surgical
techniques, feasibility, and early results.4-7 Growing experi-
ence with this technique led to its application in patients with
decreased left ventricular function.8 However, complications
with the beating-heart anastomosis have been reported2 and
seen in cases performed by experts at MIDCAB conferences.
In our clinical setting, we have seen referrals for PTCA and
redo CAB after anastomotic failure in patients undergoing
MIDCAB, and we have reported our concerns with the proce-
dure.9 The case reported here is the first one in which we have
had to perform a cardiac transplantation after failed MIDCAB
and, to our knowledge, the first reported cardiac transplanta-
tion after an unsuccessful MIDCAB procedure.
Summary. Recent experience at our institution and others
supports the feasibility of the MIDCAB procedure in selected
cases. Whether it can be mastered by the average cardiac sur-
geon and provide equal or better early graft patency, com-
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pleteness of revascularization, and long-term outcome remain
to be proved. In the meantime, complications of this proce-
dure should be studied to allow adequate assessment of the
risk involved.
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SHORT-TERM EFFECT OF CYCLOSPORINE ON CIRCULATING ADRENOMEDULLIN AFTER HEART
TRANSPLANTATION
Bernard Geny, MD, PhD, Hélène Hardy, Eliane Lampert, MD, Anne Charloux, MD, Arnaud Charpentier, MD, Jean Lonsdorfer,
MD, Pascal Haberey, MD, and François Piquard, PhD, Strasbourg, France
Adrenomedullin (ADM) is a newly discovered potent
endogenous vasorelaxing and natriuretic peptide produced by
vascular smooth muscle and endothelial cells.1 Secreted by
the failing human heart in proportion to the severity of the
disease, ADM has been proposed to oppose the local and cir-
culating vasoconstrictive and sodium-retaining factors during
heart disease.2
Cardiac transplantation, an important surgical treatment for
end-stage heart failure, partially normalizes the neurohu-
moral activation, but heart transplant recipients generally
have hypertension and body fluid volume expansion. This
may explain why both cardiac hormones, atrial and brain natri-
uretic peptides, remain elevated after heart transplantation.3
Consistently, ADM has recently been reported to be elevated
in heart transplant recipients in relation to cyclosporine
(CsA) therapy (INN: ciclosporin), suggesting that ADM
might be a compensatory mechanism to offset further CsA-
induced development of cardiac or renal dysfunction.4
However, whether CsA acutely increases the third cardiac
hormone, ADM, in heart transplant recipients remains
unknown.
Methods and results. Six heart transplant recipients gave
informed consent and participated in the study, which was
approved by the institutional review board for human studies.
Resting values of plasma ADM, CsA, and creatinine, together
with systemic blood pressure, were determined with the
patient in the supine position, and the time courses of both
plasma ADM and CsA were obtained simultaneously during
the 7 hours after oral CsA administration (125 mg twice a
day). Plasma ADM concentration was determined by
radioimmunoassay with kits from Peninsula Laboratories
(Belmont, Calif), after extraction by Sep-Pak C18 cartridges
(Waters Corporation, Milford, Mass.). Total blood cyclo-
sporinemia was determined by immunoenzymatic assay
using kits from Behring Diagnostics Inc (Cupertino, Calif).
Heart transplant recipients were 47 ± 4 (mean ± SEM) years
old, weighed 70 ± 3 kg, and the delay since transplantation was
44 ± 9 months. Systolic and diastolic blood pressures were 157
± 9 and 98 ± 4 mm Hg, respectively, and serum creatinine con-
centration was 108 ± 7 m mol/L. Circulating ADM was higher
than control values (110 ± 17 vs 20 ± 3 pmol/L in heart trans-
plant recipients and control subjects, respectively; analysis of
variance, P < .0001) and tended to correlate positively with
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